Jakafi 20 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FCHV5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $21,100
Award facts
- Contract value 100% obligated
- $21,099.79 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Jakafi 20 mg tablets (60-count units) valued at $21,099.79. The delivery order, issued on January 7, 2026, with an ultimate completion date of January 8, 2026, utilizes firm fixed-price pricing and carries no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036.
The PPV-G GEN V program, part of the broader $30.3 billion DLA acquisition strategy, establishes multiple regional prime vendor contractors authorized to provide comprehensive pharmaceutical products and medical consumables to support Department of Defense healthcare operations globally. DMS Pharmaceutical Group, which has been registered in the System for Award Management since July 2001, has demonstrated substantial federal contracting activity through numerous delivery orders across diverse therapeutic categories, including oncology treatments, immunosuppressants, vaccines, specialty pharmaceuticals, and routine medications. The company operates as a prime contractor with no identified subcontractor relationships, positioning it as a critical pharmaceutical supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FCHV5?
SPE2DR26FCHV5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 7, 2026.
How much is contract SPE2DR26FCHV5 worth?
The government has obligated $21,100 on SPE2DR26FCHV5.
Is contract SPE2DR26FCHV5 an order under another contract?
Yes. SPE2DR26FCHV5 is a delivery order under SPE2DR25D9113, an indefinite delivery contract.
Was contract SPE2DR26FCHV5 competed?
The extent of competition for SPE2DR26FCHV5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award